Detection of Proximal Coronary Artery Disease in the Work-up for Transcatheter Aortic Valve Implantation Using CTA (From the DEPICT CTA Database) (DEPICT CTA)

July 26, 2020 updated by: J.P.S Henriques, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Background: Computed tomography angiography (CTA) is already used in the work-up for transcatheter aortic valve implantation (TAVI) and could partially replace invasive coronary angiography (CAG) to rule out proximal coronary lesions.

Objectives: To assess the diagnostic accuracy and yield of pre-TAVI CTA to detect coronary lesions (≥50% DS and ≥70% DS) in the proximal coronary segments on a per-patient and a per-segment level.

Methods: The DEPICT CTA database consists of individual patient data of four studies that analysed the diagnostic accuracy of pre-TAVI CTA to detect coronary lesions. For this analysis, diagnostic accuracy was assessed in the left main and the three proximal coronary segments.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Methods Objectives To assess the diagnostic accuracy and yield of pre-TAVI CTA to detect coronary lesions (≥50% DS and ≥70% DS) in the proximal coronary segments on a per-patient and a per-segment level. The secondary objective was to perform a subgroup analysis of the individual included studies and to assess the influence of atrial fibrillation and heart rate on the diagnostic accuracy.

Literature search and study selection Studies were selected from our previous systematic review and meta-analysis on the diagnostic accuracy of CTA for the detection of significant CAD in TAVI work-up [4]. These studies were supplemented with studies that were retrieved by an updated literature search in OVID MEDLINE (including Epub Ahead of Print, In-Process & Other Non-Indexed Citations) and OVID EMBASE from January 1, 1946 to October 01, 2019. Studies were excluded if they were not reporting original data of patients who received both pre-procedural multi-detector computed tomography (MDCT) and CAG for the evaluation of CAD in the work-up of TAVI. The authors of 8 studies were approached to jointly perform a meta-analysis of individual patient data. The authors of 4 studies could accommodate the data for a per segment analysis [5-8]. The methodological quality of the included studies was assessed using the modified Quality Assessment of Studies of Diagnostic Accuracy Included in Systematic Reviews-2 criteria (QUADAS-2) [9].

Data collection The data sets included patient characteristics regarding age, sex, body mass index (BMI) and the heart rate during CT-scan. Information about co-morbidities included the presence of diabetes mellitus, atrial fibrillation, hypercholesterolemia, peripheral atrial disease, hypertension, a history of smoking, presence of CAD and a history of PCI or coronary artery bypass grafting. Technical CT scanner information included scanner type, number of detector rows, number of slices, detector width, CT scanner rotation time, scan protocol and settings (tube voltage and tube current), contrast agent type and volume, dose length product, and nitroglycerine use.

The coronary segments were categorized in three categories: lesions <50% DS, lesion ≥50-70% DS or lesions ≥70% DS), according to the 18-segment coronary model of the Society of Cardiovascular Computed Tomography or the American Heart Association modified 15-segment model [10,11]. All studies used a cut-off of ≥50% diameter stenosis to determine the presence of obstructive CAD. Three out of four studies also used a cut-off value of ≥70% DS [5,7,8], which were used for an additional analysis of the diagnostic accuracy to detect ≥70% DS proximal obstructive coronary lesions. If a segment had poor image quality or severe motion artefacts, it was labelled as non-diagnostic.

Statistical analysis Data analysis was performed using the statistical software R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). Continuous variables were presented as means with standard deviations (SD). The distribution of continuous variables was tested with the Shapiro-Wilk test. Categorical variables were presented as frequencies and percentages. The prevalence of proximal lesions of ≥50% DS and of ≥70% DS was computed from the measurements with invasive CAG, because revascularization with PCI is only considered in case of a proximal ≥70% DS lesion.(ref ESC guideline) Diagnostic accuracy of pre-TAVI CTA, as compared to pre-TAVI CAG, was defined as the sensitivity, specificity, positive - (PPV) and negative predictive value (NPV) and was derived from the number of true positives (TP), true negatives (TN), false positives (TP) and false negatives (FN). The analysis of the primary endpoint was performed on a per-patient and per-segment level. Diagnostic accuracy was computed for CTA to detect obstructive proximal coronary lesions of more than 50% DS and also of ≥70% DS lesions in a subgroup of patients were the data was available. All non-diagnostic segments were considered as abnormal tests and were labelled as if there was a lesion. For the per-patient analysis of diagnostic accuracy, patients were regarded as having proximal obstructive lesions if there was a minimum of one non-diagnostic segment. Diagnostic yield was defined as the number of patients that would not need an invasive CAG if pre-TAVI CTA was used as a gatekeeper to rule out obstructive proximal lesions and was derived from the sum of the negatives (TN + FN). For the subgroup analysis, we analysed the diagnostic accuracy in the individual included studies and assessed the diagnostic accuracy in the subgroups with atrial fibrillation and a heart rate <70 and ≥70 b/min. The diagnostic accuracy in the individual studies and the subgroups was assessed on a per-patient level for lesions ≥50% DS.

Study Type

Observational

Enrollment (Actual)

1060

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
    • Noord-Holland
      • Amsterdam, Noord-Holland, Netherlands, 1105AZ
        • Amsterdam UMC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients in the work-up for TAVI

Description

Inclusion Criteria:

  • Patients in the work-up for TAVI

Exclusion Criteria:

  • inability to undergo CTA

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Overall cohort
Pateints that underwent both CTA and CAG in the work-up for TAVI
Diagnostic test: Computed tomography angiography
Computed tomography angiography for the detection of proximal coronary lesions in patients in the work-up for TAVI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Diagnostic accuracy and yield of pre-TAVI CTA to detect coronary lesions (≥50% DS and ≥70% DS) in the proximal coronary segments on a per-patient and a per-segment level.
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2019

Primary Completion (Actual)

July 1, 2020

Study Completion (Actual)

July 1, 2020

Study Registration Dates

First Submitted

July 26, 2020

First Submitted That Met QC Criteria

July 26, 2020

First Posted (Actual)

July 29, 2020

Study Record Updates

Last Update Posted (Actual)

July 29, 2020

Last Update Submitted That Met QC Criteria

July 26, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Amsterdam UMC

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual patient data will be made available during or after publication of initial outcome paper

IPD Sharing Time Frame

data will be made available upon publication

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on Computed tomography angiography

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe